Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. develops clinical and preclinical biopharmaceutical programs for Wilson disease and oncology radiopharmaceuticals. News about MNPR centers on ALXN1840, also described as tiomolibdate choline, a late-stage investigational oral therapy for Wilson disease, including analyses from the Phase 3 FoCus trial, copper-balance data, neurology and hepatology conference presentations, and related peer-reviewed publications.
Company updates also cover the MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers, including MNPR-101-Zr imaging activity, MNPR-101-Lu therapeutic development and IND clearance, and preclinical MNPR-101-Ac work. Recurring corporate themes include financial results, public offerings, balance-sheet updates, and commercial or executive infrastructure as the company advances its pipeline.
Monopar Therapeutics (MNPR) reported a net loss of $1.4 million, or $0.14 per share, for Q2 2020, an increase from a $0.9 million loss in Q2 2019. Cash and cash equivalents stood at $12.5 million. Key developments include a 50/50 collaboration with NorthStar to create Radio-Immuno-Therapeutics to treat severe COVID-19, utilizing Monopar's MNPR-101. Both the Validive and camsirubicin clinical trials are on track to commence dosing in H2 2020. R&D expenses rose to $0.8 million due to clinical preparations and staffing.
Monopar Therapeutics (Nasdaq: MNPR) and NorthStar Medical Radioisotopes announced a provisional patent application for a treatment targeting the Urokinase Plasminogen Activator Receptor (uPAR) in severe COVID-19 patients. This application aims to create precision radioimmunotherapeutics (uPRITs) that selectively destroy activated white blood cells, potentially reducing mortality rates from cytokine storms. The collaboration aims to leverage both companies' expertise to enhance treatment efficacy. If granted, the patent will provide exclusivity for the use of uPRITs in severe COVID-19 and respiratory diseases.
Monopar Therapeutics and NorthStar Medical Radioisotopes have formed a 50/50 collaboration to develop Radio-Immuno-Therapeutics (RITs) targeting severe COVID-19. This partnership aims to combine NorthStar's expertise in medical radioisotope production with Monopar's MNPR-101 antibody. The goal is to create a selective treatment that can kill aberrantly activated immune cells responsible for cytokine storms in COVID-19 patients. The collaboration plans to conduct development programs to potentially transform Monopar's monoclonal antibodies into effective RITs against severe COVID-19.
Monopar Therapeutics (Nasdaq: MNPR) reported its first quarter 2020 financial results, highlighting a net loss of $1.1 million ($0.10 per share), improved from a $1.4 million loss in Q1 2019. Cash and cash equivalents amounted to $12.6 million. The company is advancing its Validive Phase 2b/3 clinical trial, now set to start in the second half of 2020, with a focus on reducing enrollment challenges due to COVID-19. Additionally, the camsirubicin Phase 2 clinical trial is progressing in collaboration with GEIS, targeting advanced soft tissue sarcoma.